Newsletter

Subscribe and recieve updates on this company.

Text STOCKS to 72727 for mobile alerts

We are excited to present Fibrocell Science Inc. (NASDAQ: FCSC).

Full DD Report for FCSC

You must become a subscriber to view this report.


Recent News from (NASDAQ: FCSC)

Abeona Therapeutics: A Potential Leader In Gene Therapy
Company overview Abeona Therapeutics (ABEO) is a clinical stage biopharmaceutical company focused on gene and cell therapy for rare genetic disease. This company has a long history starting from Access Pharmaceuticals established in 1974. It evolved with several mergers and acquisitions in...
Source: SeekingAlpha
Date: November, 01 2018 11:11
Fibrocell Receives Guidance from FDA on Phase 3 Clinical Trial Design for FCX-007
Company Plans to Submit Phase 3 Protocol to FDA in Fourth Quarter of 2018 and Commence Trial in First Half of 2019  EXTON, Pa., Oct. 25, 2018 (GLOBE NEWSWIRE) -- Fibrocell Science, Inc. (NASDAQ: FCSC), a gene therapy company focused on transformational autologous cell-based th...
Source: GlobeNewswire
Date: October, 25 2018 08:00
Gene therapy players under pressure
The Nasdaq's selloff notwithstanding, most gene therapy stocks are in the red. This morning, Sangamo Therapeutics ( SGMO -21.1% ) reported data on SB-913 that disappointed investors. More news on: Sangamo Therapeutics, Inc., AVROBIO, MeiraGTx Holdings plc, Healthcare stocks news, Stocks ...
Source: SeekingAlpha
Date: September, 05 2018 10:58
Premarket Gainers as of 9:05 am (09/05/2018)
PRQR +66%  on positive interim results from Phase 1/2 clinical trial of QR-110 in LCA10 patients. More news on: ProQR Therapeutics, Cronos Group, Inc., Nevsun Resources Ltd., Stocks on the move, , Read more ...
Source: SeekingAlpha
Date: September, 05 2018 09:21
Fibrocell Announces FDA Fast Track Designation of FCX-013 for Treatment of Moderate to Severe Localized Scleroderma
EXTON, Pa., Sept. 05, 2018 (GLOBE NEWSWIRE) -- Fibrocell Science, Inc. (NASDAQ:FCSC), a gene therapy company focused on transformational autologous cell-based therapies for skin and connective tissue diseases, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast...
Source: GlobeNewswire
Date: September, 05 2018 08:00
Fibrocell to Present at 20th Annual Rodman & Renshaw Global Investment Conference
EXTON, Pa., Aug. 29, 2018 (GLOBE NEWSWIRE) -- Fibrocell Science, Inc. (NASDAQ: FCSC), a gene therapy company focused on transformational autologous cell-based therapies for skin and connective tissue diseases, today announced that John Maslowski, President and Chief Executive Officer, will ...
Source: GlobeNewswire
Date: August, 29 2018 08:00
FDA and NIH to loosen oversight of gene therapy development
Citing the need to safely expedite the development of gene therapies and the rapid scientific advances related to the gene editing, the FDA and NIH are backing trimmed down oversight of relevant clinical trials, specifically eliminating the duplication of oversight related to initial study...
Source: SeekingAlpha
Date: August, 16 2018 09:47
Fibrocell Science, Inc. (FCSC) CEO John Maslowski on Q2 2018 Results - Earnings Call Transcript
Fibrocell Science, Inc. (FCSC) Q2 2018 Earnings Conference Call August 09, 2018, 08:30 ET Executives Karen Casey - IR, Manager John Maslowski - President and CEO Sean Buckley - VP, Business Administration Analysts Joe Pantginis - H.C. Wainwright Presentation Operator...
Source: SeekingAlpha
Date: August, 09 2018 12:59
Fibrocell Reports Second Quarter 2018 Financial Results and Recent Highlights
EXTON, Pa., Aug. 09, 2018 (GLOBE NEWSWIRE) -- Fibrocell Science, Inc. (NASDAQ: FCSC), a gene therapy company focused on transformational autologous cell-based therapies for skin and connective tissue diseases, today reported financial results for the second quarter ended June 30, 2018 and r...
Source: GlobeNewswire
Date: August, 09 2018 08:00
RegeneRx announces global development deal for RGN-137; shares up 5%
RegeneRx Biopharmaceuticals ( OTCQB:RGRX +5% ) announces that licensee GtreeBNT has formed a joint venture, Lenus Therapeutics, with YuYang DNA to develop RGN-137 on a global basis for the treatment of epidermolysis bullosa (EB), a rare inherited skin disorder characterized by blisters a...
Source: SeekingAlpha
Date: August, 02 2018 10:13

 


Last 5 Days Trading Activity

DateOpen PriceClose PriceHighLowVolume
2018-12-132.021.992.091.9638,576
2018-12-121.982.022.081.9149,884
2018-12-111.931.9452.051.91709,809
2018-12-101.971.972.041.86547,058
2018-12-072.041.972.091.9651,160

Last 5 Days Short Activity

DateShort VolumeTotal VolumeShort PercentageShort Indicator
2018-12-1310,50016,54263.4748Short
2018-12-1290011,3017.9639Cover
2018-12-1175,488122,70961.5179Short
2018-12-1016,16320,34179.4602Short
2018-12-072,75010,56726.0244Cover

* Short Mode

Short Analysis provided by Squeeze Report. Get a complete short report on FCSC.


About Fibrocell Science Inc. (NASDAQ: FCSC)

Logo for Fibrocell Science Inc. (NASDAQ: FCSC)

Not available

 

 

 

Current Management

  • David Pernock / CEO
  • Declan Daly / COO, CFO
  • George J. Korkos /

Current Share Structure

  • Market Cap: $16,968,440 - 05/16/2018
  • Issue and Outstanding: 28,356,351 - 03/06/2018

 


Recent Filings from (NASDAQ: FCSC)

Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: May, 10 2018
Quarterly report with a continuing view of a company's financial position
Filing Type: 10-QFiling Source: edgar
Filing Date: May, 10 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: April, 18 2018
Official notification to shareholders of matters to be brought to a vote (Proxy)
Filing Type: DEF 14AFiling Source: edgar
Filing Date: April, 02 2018
Additional proxy soliciting materials - definitive
Filing Type: DEFA14AFiling Source: edgar
Filing Date: April, 02 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: March, 19 2018
Annual report with a comprehensive overview of the company
Filing Type: 10-KFiling Source: edgar
Filing Date: March, 19 2018
Preliminary proxy statement providing notification matters to be brought to a vote
Filing Type: PRE 14AFiling Source: edgar
Filing Date: March, 19 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: March, 06 2018
Amendment to the SC 13G filing
Filing Type: SC 13G/AFiling Source: edgar
Filing Date: February, 13 2018

 

 


Daily Technical Chart for (NASDAQ: FCSC)

Daily Technical Chart for (NASDAQ: FCSC)


Stay tuned for daily updates and more on (NASDAQ: FCSC)

It most certainly could but even more important is the recent overwhelming interest in the company. Check out Investors Hub and search on Twitter

More to come on (NASDAQ: FCSC)

Do your DD and if you choose, be ready to go!


 

The Research: All source information contained in this email is from the public sources mentioned below.

 

 
 

Thank you

DD Report
@DDReports

 

 


Disclaimer: DD Report publishes reports providing information on selected companies. DD Report is not a registered investment advisor or broker-dealer. This report is provided as an information service only, and the statements and opinions in this report should not be construed as an offer or solicitation to buy or sell any security. DD Report accepts no liability for any loss arising from an investors reliance on or use of this report. An investment in FCSC is considered to be highly speculative and should not be considered unless a person can afford a complete loss of investment. DD Report has received no compensation for the publication and circulation of this report. DD Report does not own any shares of FCSC and does not buy, sell, or trade any shares of FCSC. This report contains forward-looking statements, which involve risks, and uncertainties that may cause actual results to differ materially from those set forth in the forward-looking statements. Copyright 2018 by DD Report. All rights reserved. Our Full Disclaimer: https://dd.report/disclaimer/